FMP

FMP

Enter

ACRS - Aclaris Therapeutics...

Financial Summary of Aclaris Therapeutics, Inc.(ACRS), Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug

photo-url-https://financialmodelingprep.com/image-stock/ACRS.png

Aclaris Therapeutics, Inc.

ACRS

NASDAQ

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

1.12 USD

-0.015 (-1.35%)

About

ceo

Dr. Neal S. Walker D.O., M.D.

sector

Healthcare

industry

Medical - Diagnostics & Research

website

https://www.aclaristx.com

exchange

NASDAQ

Description

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moder...

CIK

0001557746

ISIN

US00461U1051

CUSIP

00461U105

Address

640 Lee Road

Phone

484 324 7933

Country

US

Employee

86

IPO Date

Oct 6, 2015

Summary

CIK

0001557746

Exchange

NASDAQ

Industry

Medical - Diagnostic...

Sector

Healthcare

CUSIP

00461U105

ISIN

US00461U1051

Country

US

Price

1.11

Beta

0.07

Volume Avg.

679.75k

Market Cap

79.46M

Shares

-

52-Week

0.59-11.12

DCF

-0.07

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.02

P/B

-

Website

https://www.aclaristx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ACRS News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep